Antoine Decrulle
@adecrulle.bsky.social
VP Research at Eligo Bioscience at the interface between synthetic biology, microbiome, phage and CRISPR
Reposted by Antoine Decrulle
ICYMI: CRISPR–Cas therapies targeting bacteria
CRISPR–Cas therapies targeting bacteria
Nature Reviews Bioengineering, Published online: 13 May 2025; doi:10.1038/s44222-025-00311-8CRISPR–Cas tools can be designed to kill or modify specific bacteria. This Review explores the engineering of CRISPR–Cas tools and corresponding delivery strategies for the treatment of bacterial infections and modification of the microbiome.
www.nature.com
May 15, 2025 at 6:53 AM
Reposted by Antoine Decrulle
The Eligo team did it again! We just shared on biorxiv the work we did towards the development of a CRISPR-Cas therapy targeting Shiga Toxin producing E. coli (STEC). www.biorxiv.org/content/10.1...
www.biorxiv.org
March 4, 2025 at 12:31 PM
The Eligo team did it again! We just shared on biorxiv the work we did towards the development of a CRISPR-Cas therapy targeting Shiga Toxin producing E. coli (STEC). www.biorxiv.org/content/10.1...